[{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Parexel"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LaSanta S A S","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"LaSanta S A S","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LaSanta S A S \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaSanta S A S \/ Inapplicable"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"NB1000S","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novome Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"E2Bio Life Sciences","sponsor":"Hematology Center after Prof. R. Yeolyan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"E2Bio Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan","highestDevelopmentStatusID":"7","companyTruncated":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ AzurRx BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ AzurRx BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Ziauddin University","sponsor":"Hilton Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ziauddin University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ziauddin University \/ Hilton Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Ziauddin University \/ Hilton Pharma"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"7","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Private Placement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Bausch Health","highestDevelopmentStatusID":"7","companyTruncated":"Cedars-Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Amy Lightner","sponsor":"Ossium Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ossium vBM-MSC","moa":"Bone marrow cell","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Amy Lightner","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amy Lightner \/ Ossium Health","highestDevelopmentStatusID":"7","companyTruncated":"Amy Lightner \/ Ossium Health"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Argon Medical Devices","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Argon Medical Devices","highestDevelopmentStatusID":"7","companyTruncated":"University of Alabama at Birmingham \/ Argon Medical Devices"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"NM-002","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"PrecisionBiotics Group Ltd.","sponsor":"Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"PrecisionBiotics Group Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrecisionBiotics Group Ltd. \/ Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"PrecisionBiotics Group Ltd. \/ Atlantia Food Clinical Trials Ltd."},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"EP-104IAR","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Changhai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TH-SC01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Changhai Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Changhai Hospital"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Xiangya Hospital, Central South University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TH-SC01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Xiangya Hospital, Central South University","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Xiangya Hospital, Central South University"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Longum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc."}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
